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Abstract
Objective: To investigate the added diagnostic value of 3.0 Tesla breast MRI over conventional breast imaging in the
diagnosis of in situ and invasive breast cancer and to explore the role of routine versus expert reading.
Materials and Methods: We evaluated MRI scans of patients with nonpalpable BI-RADS 3–5 lesions who underwent
dynamic contrast-enhanced 3.0 Tesla breast MRI. Initially, MRI scans were read by radiologists in a routine clinical setting. All
histologically confirmed index lesions were re-evaluated by two dedicated breast radiologists. Sensitivity and specificity for
the three MRI readings were determined, and the diagnostic value of breast MRI in addition to conventional imaging was
assessed. Interobserver reliability between the three readings was evaluated.
Results: MRI examinations of 207 patients were analyzed. Seventy-eight of 207 (37.7%) patients had a malignant lesion, of
which 33 (42.3%) patients had pure DCIS and 45 (57.7%) invasive breast cancer. Sensitivity of breast MRI was 66.7% during
routine, and 89.3% and 94.7% during expert reading. Specificity was 77.5% in the routine setting, and 61.0% and 33.3%
during expert reading. In the routine setting, MRI provided additional diagnostic information over clinical information and
conventional imaging, as the Area Under the ROC Curve increased from 0.76 to 0.81. Expert MRI reading was associated with
a stronger improvement of the AUC to 0.87. Interobserver reliability between the three MRI readings was fair and moderate.
Conclusions: 3.0 T breast MRI of nonpalpable breast lesions is of added diagnostic value for the diagnosis of in situ and
invasive breast cancer.
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Introduction
Dynamic contrast-enhanced magnetic resonance imaging
(MRI) of the breast has become mainstream for the detection
and characterization of breast lesions in clinical practice [1–3].
Current indications for breast MRI include screening of high-risk
populations, monitoring of the treatment response in patients
receiving neoadjuvant chemotherapy, tumor detection in patients
with metastases of an unknown primary, and evaluation of silicone
breast prostheses [4,5]. Two randomised controlled trials have
studied the impact of preoperative breast MRI on the reoperation
rate after breast-conserving surgical treatment [6,7]. In these
studies, the addition of breast MRI to conventional imaging did
not reduce the number of additional surgical interventions, e.g.
repeat lumpectomy or mastectomy. Preoperative breast MRI is
therefore currently only indicated in a selection of patients, e.g. in
patients with invasive lobular carcinoma, patients with a
discrepancy in lesion size of more than 1 cm between mammog-
raphy and ultrasound, and patients eligible for partial breast
irradiation, in whom the clinical benefit of preoperative breast
MRI is more clear [8].
Several studies assessed the overall diagnostic accuracy of breast
MRI in patients with suspicious breast lesions, reporting a high
sensitivity of around 90%, and a considerably lower specificity of
70–75% [2,9,10]. However, few articles addressed the diagnostic
value of MRI in addition to conventional imaging (i.e. mammog-
raphy and ultrasound) [11,12]. Furthermore, most breast MRI
studies were performed using a 1.5 Tesla (T) MRI system [10].
Imaging at higher field strength may be beneficial because of the
higher signal-to-noise ratio (SNR). Only one relatively small study
reported a higher diagnostic accuracy for breast MRI at 3.0 T
compared to 1.5 T [13]. To our knowledge, large studies assessing
the overall diagnostic performance of breast MRI at 3.0 T are
lacking.
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The aim of this study was to assess the added diagnostic value of
3.0 Tesla breast MRI in patients with nonpalpable breast disease
who were referred for histological biopsy. In addition, we
evaluated interobserver variability between routine and expert
reading for the evaluation of 3.0 T breast MRI.
Materials and Methods
Patients
This study was conducted using data from the MONET study
(MR mammography Of Nonpalpable BrEast Tumors), a multi-
center randomized controlled trial (NCT00302120) designed to
assess the impact of dynamic contrast-enhanced breast MRI on
the re-excision rate of women with nonpalpable breast lesions. The
study protocol was approved by the institutional review boards of
the University Medical Center Utrecht, Diakonessen Hospital
Utrecht, and the Albert Schweitzer Hospital, and written informed
consent was obtained from all patients. Detailed methods were
described elsewhere [6]. Briefly, between January 2006 and May
2009, 463 patients with nonpalpable breast lesions classified as BI-
RADS 3-5 on mammography or ultrasound with an indication for
histological biopsy, were randomly allocated to routine clinical
care or to routine clinical care with an additional 3.0 T breast
MRI. Mammography and breast ultrasound were read in a
routine clinical setting by several radiologists at the center of
patient inclusion. In the present study, we included only patients
who were randomized to undergo additional breast MRI.
Histological analysis was performed and lesions were classified as
benign or malignant (i.e. ductal carcinoma in situ or invasive
carcinoma) based on biopsy (in case of a benign lesion) or the
surgical specimen. Only the index lesions (i.e. the nonpalpable BI-
RADS 3–5 lesion for which patients were included) were included
in the analyses.
MR imaging
MR imaging was performed prior to large-core needle biopsy
(LCNB). All breast MRI scans were performed on a 3.0 T clinical
MR system (Achieva, Philips Healthcare, Best, the Netherlands) at
the University Medical Centre Utrecht. The system employs
gradient amplitudes up to 80 mT/m and slew rates up to
200 mT/m/ms. Patients were placed in prone position on a
dedicated, four-channel phased-array bilateral breast coil (MRI
devices, Wu¨rzburg, Germany). All series were acquired using
SENSE parallel imaging techniques. The scan protocol included a
transverse, dynamic contrast-enhanced fat-suppressed T1-weight-
ed gradient echo series (TE/TR 1.3/3.4 ms; flip angle 10u; FOV
3206320 mm2, acquired voxel size 0.9160.9162.00 mm3, recon-
structed voxel size 0.8360.8361.00 mm3; dynamic scan duration
60 sec). For the contrast-enhanced series, fat suppression was
employed using SPAIR fat suppression. One scan was acquired
before, and five scans were acquired immediately after adminis-
tration of 0.1 mmol/kg Gadolinium-DTPA (Magnevist, Schering,
Germany). Also, a transverse high-resolution fat-suppressed T1-
weighted fast gradient echo series (TE/TR 1.7/4.5 ms; inversion
delay SPAIR 130 ms; flip angle 10u; FOV 3406340 mm2,
acquired voxel size 0.6660.6661.6 mm3, reconstructed voxel size
0.6660.6660.80 mm3) and a fat-suppressed T2-weighted spin
echo series (TE/TR 120/9022 ms; inversion delay SPAIR
125 ms; flip angle 90u; FOV 3406340 mm2, acquired voxel size
1.0161.3162.0 mm3, reconstructed voxel size
0.6660.6662.00 mm3) were acquired.
Image analysis
During the MONET study, MRI examinations were initially
read by four breast radiologists in a routine clinical setting
according to the BI-RADS MRI lexicon as proposed by the
American College of Radiology [14]. For this present study, all
index lesions were re-evaluated by two trained and dedicated
breast radiologists in a review setting. They both had about seven
years experience in reading breast MRI and were not involved in
routine reading. According to the BI-RADS MRI lexicon, lesions
were classified as focus, mass, or non-mass like enhancement.
Subsequently, the corresponding features (i.e. shape, margin and
mass enhancement for mass lesions, distribution modifiers and
internal enhancement for non-mass lesions) were assessed. During
expert MRI reading, information on the mammography images
was provided. Expert readers were blinded for histological results
and a software tool (CADstream, Confirma, Chicago, Illinois) for
image post-processing was used for a standardized analysis and
interpretation of the dynamic contrast-enhanced images. CAD-
stream is a commercially available computer-aided detection
system. Color overlays on the dynamic MR images were used to
indicate the threshold of initial enhancement. Furthermore, the
color overlay allows differentiation between the three types of
enhancement (persistent, plateau, and washout) in the late phase
after contrast injection. Expert readers were allowed to exclude
MRI examinations if, to their opinion, the image quality was
insufficient for analysis.
Statistics
Univariate analysis was performed to assess differences between
patients with benign and malignant lesions. Continuous variables
were analysed using the independent sample T-test. For categor-
ical variables, differences in proportions were tested using the
Pearson’s chi-squared test or the Fisher’s exact test. Clinical,
mammographic and ultrasound features that were most signifi-
cantly associated with malignancy were introduced into a first
model. Three other models were constructed after the addition of
the three MRI readings. For every ten malignancies, one
determinant was allowed to be included in the logistic regression
model. Discrimination between benign and malignant lesions was
estimated by the Area Under the Receiver Operating Character-
istic (ROC) Curve (AUC). Differences between AUCs were tested
according to Hanley and McNeil [15]. Calibration was measured
using the Hosmer-Lemeshow goodness-of-fit test. To calculate
sensitivity and specificity of the three MRI readings, BI-RADS
classifications of 1 and 2 were considered as negative, and BI-
RADS 3–5 as positive test results. The same cut-off value (i.e., BI-
RADS 1 and 2 for benign lesions and BI-RADS 3–5 for malignant
lesions) was used to calculate the reliability using k statistics. In
addition, interobserver agreement, defined as the degree to which
ratings are identical (the measurement error) was calculated using
the proportion of agreement [16]. Differences were tested between
all three MR readings (routine reading, expert reader 1 and 2). A k
value below 0.20 indicated poor agreement; 0.21–0.40 fair
agreement; 0.41–0.60 moderate agreement; 0.61–0.80 good
agreement; and a k value of 0.81–1.00 indicated very good
agreement [17]. Statistical analyses were performed using the
software packages SPSS (version 20.0, Chicago, Illinois).
Results
Patients
MRI examinations of 207 patients were analyzed. The mean
age of patients was 55.1 years and 60.2% of patients were referred
by the national breast cancer screening program (Table 1).
3T Breast MRI for Diagnosis of Nonpalpable Lesions
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Mammography showed microcalcifications only in 121/207
(58.5%) patients. LCNB showed a malignant lesion in 78/207
(37.7%) patients. Thirty-three of 78 (42.3%) patients were
diagnosed with pure ductal carcinoma in situ and 45/78 (57.7%)
with invasive breast cancer, with or without an in situ component.
Diagnostic performance of MRI
With routine MRI reading, 15/31 (48.4%, 95% CI 32.0–65.2)
of BI-RADS 3 lesions, 19/31 (61.3%, 95% CI 43.8–76.3) of BI-
RADS 4 lesions, and 18/19 (94.7%, 95% CI 75.4–99.1) of BI-
RADS 5 lesions were proven malignant by histology. Table 2
shows the different BI-RADS classifications of routine and expert
readers versus the histological outcome. For routine reading, the
sensitivity of MRI for the detection of malignancy was 66.7% and
specificity was 77.5% (Table 3). Thus, in 26/78 (33.3%) patients,
the malignant lesion was not detected on MRI; in 21/26 (80.8%)
patients this concerned pure DCIS without an invasive compo-
nent.
Expert reader 1 judged nine MRI examinations to be of
insufficient image quality for assessment. These included three
pure DCIS and six benign lesions. Positive predictive values were
33.3% (95% CI 20.2–49.7), 60.0% (95% CI 47.4–71.4), and 100%
(95% CI 83.2–100.0) for BI-RADS 3, 4, and 5 lesions,
respectively. Sensitivity was 89.3% and specificity was 61.0%. In
8/75 (10.7%) of patients, the malignant lesion (pure DCIS in all
cases) was not seen on MRI.
Expert reader 2 rated fourteen MRI examinations of insufficient
image quality, and one MRI examination was not analyzed
unintentionally. These were three malignant and twelve benign
lesions. Positive predictive values were 17.1% (95% CI 8.5–31.3),
55.6% (95% CI 45.8–65.0) and 100% (95% CI 70.1–100.0) for
lesions classified as BI-RADS 3, 4 and 5, respectively. Sensitivity
was 94.7% and specificity was 33.3%. In 4/75 (5.3%) of patients,
the malignant lesion (pure DCIS in all cases) was not seen on MRI.
Figure 1 and 2 show some typical examples of mammography and
MR imaging in two patients.
Added diagnostic value of 3.0 T MR imaging
The logistic regression model with clinical characteristics (i.e.,
age and breast cancer in first degree relatives) and conventional
Table 1. Baseline table presenting clinical patient characteristics and features on mammography and ultrasound for the 207 index
lesions.
Benign (%) Malignant (%) p-value Total (%)
Clinical characteristics
Number of patients 129 (62.3) 78 (37.7) 207 (100)
Age in years, mean 6 SD (n = 207) 52.969.8 58.767.6 0.00* 55.169.5
BMI in kg/m2, mean 6 SD (n = 201) 25.063.8 26.263.8 0.026* 25.463.8
Breast cancer in first degree relative (n = 204) 19 (15.1) 24 (30.8) 0.008‘ 43 (21.1)
Presence of clinical symptoms (n = 204) 42 (33.3) 16 (20.5) 0.049‘ 58 (28.4)
Detected in screening program (n = 201) 65 (51.6) 56 (74.4) 0.001‘ 121 (60.2)
Mammography
Type of finding (n=207)
Microcalcifications only 80 (62.0) 41 (52.6) 0.37‘ 121 (58.5)
Mass lesion (with/without microcalcifications) 39 (30.2) 28 (35.9) 67 (32.4)
Other 10 (7.8) 9 (11.5) 19 (9.2)
BI-RADS classification (n =207)
BI-RADS 1 or 2 a 8 (6.2) 0 (0.0) 0.000& 8 (3.9)
BI-RADS 3 56 (43.4) 23 (29.5) 79 (38.2)
BI-RADS 4 64 (49.6) 45 (57.7) 109 (52.7)
BI-RADS 5 1 (0.8) 10 (12.8) 11 (5.3)
Ultrasound
Performed (n = 207) 94 (72.9) 67 (85.9) 0.029‘ 161 (77.8)
Type of finding (n=161)
No lesion 57 (60.6) 31 (46.3) 0.19‘ 88 (54.7)
Solid lesion 28 (29.8) 28 (41.8) 56 (34.8)
Other b 9 (9.6) 8 (11.9) 17 (10.6)
BI-RADS classification (n =160)
BI-RADS 1 or 2 63 (67.7) 34 (50.7) 0.000‘ 97 (60.6)
BI-RADS 3 19 (20.4) 6 (9.0) 25 (15.6)
BI-RADS 4 10 (10.8) 16 (23.9) 26 (16.3)
BI-RADS 5 1 (1.1) 11 (16.4) 12 (7.5)
*independent sample T-test, ‘chi-square test, &Fisher’s exact test
aoccult or benign lesion on mammography (BI-RADS 1 or 2), classified as BI-RADS 3, 4 or 5 on ultrasound.
bcystic lesions, hypoechoic areas not otherwise specified, and areas of architectural distortion.
doi:10.1371/journal.pone.0094233.t001
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imaging (i.e., mammography and ultrasound) had an AUC of 0.76
(95% CI 0.69–0.83). In the routine setting, MRI was of added
diagnostic value over clinical characteristics and conventional
imaging: after the addition of routine MRI reading to the
regression model, the AUC increased to 0.81 (95% CI 0.75–0.88)
with a p-value ,0.05. Expert MRI reading was associated with an
even stronger improvement in AUC, from 0.76 (95% CI 0.69–
0.83) to 0.87 (95% CI 0.82–0.92) for reader 1 and 0.87 (95% CI
0.81–0.92) for reader 2. The differences between the AUC’s with
and without the addition of MRI were statistically significant for
both expert readers (p-value ,0.001). All models showed good
calibration (p.0.1) (Figure 3).
Interobserver reliability and agreement
The proportion of agreement between the three observers
varied between 56.8 and 78.8% for the three MRI readings
(Table 4). Reliability between routine reading and expert reader 1
(kappa 0.59) and between expert reader 1 and expert reader 2
(kappa 0.48) was moderate. The reliability between routine
reading and expert reader 2 was fair (kappa of 0.22).
Discussion
Our results show that 3.0 Tesla breast MRI of nonpalpable
lesions is of added diagnostic value in the diagnosis of in situ and
invasive breast cancer. Both during routine and expert reading,
addition of breast MRI allowed better discrimination between
benign and malignant disease, with AUC’s increasing from 0.76 to
0.81 with routine MRI reading and from 0.76 to 0.87 for expert
reading. Although many studies assessed the sensitivity and
specificity of breast MRI in itself, only a few studies have looked
at the added value of breast MRI when combined with
mammography and ultrasound. Berg et al. described that the
combination of mammography, clinical examination and MR
imaging was more sensitive (99.4%) for invasive cancer than any
other test or combination of different tests [11]. Malur et al.
reported a sensitivity of 99.4% when combining mammography,
ultrasound and MR imaging [12]. No studies have assessed the
added value of breast MRI over conventional imaging in patients
with nonpalpable breast lesions. Due to the introduction of breast
cancer screening programs, the detection of clinically occult, often
nonpalpable, suspicious lesions on mammography has increased
over the years [18]. A large percentage of these patients present
with microcalcifications on mammography. Ruling out DCIS in
these patients can be a diagnostic challenge: mammography has a
Table 2. BI-RADS MRI classifications for routine and expert MRI reading.
Benign (%) In situ (%) Invasive (%) Total (%)
Routine reading
BI-RADS classification (207)
BI-RADS 1/2 100 (77.5) 21 (63.6) 5 (11.1) 126 (60.9)
BI-RADS 3 16 (12.4) 6 (18.2) 9 (20.0) 31 (15.0)
BI-RADS 4 12 (9.3) 6 (18.2) 13 (28.9) 31 (15.0)
BI-RADS 5 1 (0.8) 0 (0.0) 18 (40.0) 19 (9.2)
Expert reader 1
BI-RADS classification (198)
BI-RADS 1/2 75 (61.0) 8 (26.7) 0 (0.0) 83 (41.9)
BI-RADS 3 24 (19.5) 7 (23.3) 5 (11.1) 36 (18.2)
BI-RADS 4 24 (19.5) 15 (50.0) 21 (46.7) 60 (30.3)
BI-RADS 5 0 (0.0) 0 (0.0) 19 (42.2) 19 (9.6)
Expert reader 2
BI-RADS classification (192)
BI-RADS 1/2 39 (33.3) 4 (12.9) 0 (0.0) 43 (22.4)
BI-RADS 3 34 (29.1) 4 (12.9) 3 (6.8) 41 (21.4)
BI-RADS 4 44 (37.6) 21 (67.7) 34 (77.3) 99 (51.6)
BI-RADS 5 0 (0.0) 2 (6.5) 7 (15.9) 9 (4.7)
doi:10.1371/journal.pone.0094233.t002
Table 3. Sensitivity and specificity for routine and expert reading of 3.0 T breast MRI.
Sensitivity (95% CI) Specificity (95% CI) AUC (95% CI)
Routine reading 66.7 (55.6–76.1) 77.5 (69.6–83.9) 0.81 (0.75–0.88)
Expert reader 1 89.3 (80.3–94.5) 61.0 (52.2–69.1) 0.87 (0.82–0.92)
Expert reader 2 94.7 (87.0–97.9) 33.3 (25.4–42.3) 0.87 (0.81–0.92)
doi:10.1371/journal.pone.0094233.t003
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high sensitivity for the detection of microcalcifications, but also
leads to many biopsies in benign cases [19,20].
In this study, sensitivity was 66.7% and specificity was 77.5% for
routine reading of breast MRI. For the two expert readers, these
sensitivities increased to 89.3% and 94.7%. This increase in
sensitivity was accompanied with a decrease in specificity to 61.0%
and 33.3%. The low specificity of 33.3% of expert reader 2 was
caused by the high percentage of benign lesions, which were
classified as BI-RADS 3 (29.1%) and BI-RADS 4 (37.6%). This
reader had, however, the highest sensitivity among all readings.
Next to the assessment of sensitivities and specificities, we
specifically investigated the diagnostic performance of the different
imaging methods using ROC analyses. In clinical practice, the BI-
RADS lexicon is used to classify lesions in categories with different
risks on malignancy. For calculating measures of diagnostic
performance (i.e. sensitivity and specificity), a certain cut-off point
must be chosen. The area under the ROC curve however is able
to show the diagnostic performance irrespective of a cut-off point,
and therefore reflects the overall discriminative value of various
tests [21].
In this study, MR images were read following the BI-RADS-
MRI lexicon, using T1 and T2 weighted series for morphological
analysis of the lesion and dynamic contrast-enhanced series for
analysis of the enhancement pattern of the lesions over time. This
yields a proven high sensitivity for the characterization of benign
versus malignant breast lesions [5]. Currently, other promising
MR techniques such as diffusion weighted imaging and MR
spectroscopy are becoming more widely available, which may
further improve the diagnostic accuracy of breast MRI [22].
Furthermore, the results of this study can probably be extrapolated
to studies performed at 1.5 T imaging, because of the comparable
results of breast MRI at 3.0 T and 1.5 T MRI [13]. Our study,
however, is one of the few studies which has evaluated a relatively
large patient population with small breast lesions on a 3.0 T MRI
system.
Both the COMICE and the MONET trial did not show an
added value of breast MRI for the surgical outcome of breast
cancer patients [6,7]. Turnbull et al. reported no reduction in the
reoperation rate after the addition of breast MRI. Both in the MRI
group and in the control group, the percentage of patients
requiring reoperation was 19% [7]. The MONET study showed
even a higher percentage of re-excisions in the MRI group (34%)
versus the control group (12%) [6]. In this study, we only report on
the diagnostic performance of breast MRI. Unfortunately, it is not
feasible to repeat the analyses for the therapeutic outcome of this
trial for the two expert readers. However, while preoperative MRI
nowadays is only used in a selection of patients, our results show
that MRI does have additional value over baseline characteristics
Figure 1. Craniocaudal (a) and mediolateral oblique (b) mammogram of a 52 year old patient with BI-RADS 5 microcalcifications in
the left lateral upper quadrant. Ultrasound imaging was unremarkable (BI-RADS 1). During routine reading, the MRI examination was classified as
BI-RADS 4. Both expert reader 1 and 2 classified the lesion as an area of non-mass like enhancement with clumped internal enhancement and a
segmental distribution. Kinetics showed a rapid initial rise and a plateau stage during the delayed phase. A BI-RADS 4 and 5 classification was given
by expert reader 1 and 2, respectively. Figure 1 shows the dynamic contrast-enhanced MRI (c) and the MR image imported in the CAD software (d).
The color-coded overlay indicates the type of enhancement after contrast injection in the late phase. Red, yellow and blue illustrate a washout-,
plateau- and persistent- enhancement curve, respectively. Stereotactic biopsy and surgery both showed DCIS without an invasive component.
doi:10.1371/journal.pone.0094233.g001
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Figure 2. Craniocaudal (a) and mediolateral oblique (b) mammogram of a 40 year old, asymptomatic woman underwent
mammography during follow-up after right-sided breast cancer, for which she underwent mastectomy. Mammography showed BI-
RADS 4 microcalcifications in the lateral upper quadrant of the left breast. Ultrasound imaging was unremarkable (BI-RADS 1). During routine MRI
reading, a BI-RADS 1 classification was assigned. Expert reader 1 reported an area of non-mass-like enhancement with a diffuse distribution,
heterogeneous internal enhancement and classified MR imaging as BI-RADS 4. In addition, expert reader 2 described an area of non-mass-like
enhancement with a segmental distribution and clumped internal enhancement, and reported a BI-RADS 4. Kinetics showed a rapid initial rise and a
plateau stage during the delayed phase. Figure 2 shows the dynamic contrast-enhanced MRI (c) and the MR image imported in the CAD software (d).
The color-coded overlay indicates the type of enhancement after contrast injection in the late phase. Yellow and blue illustrate a plateau- and
persistent- enhancement curve, respectively. Stereotactic biopsy showed normal breast tissue with minor fibrocystic changes and the extensive
presence of microcalcifications.
doi:10.1371/journal.pone.0094233.g002
Figure 3. ROC analysis shows an AUC of 0.76 for the model with clinical characteristics and conventional imaging, which is
displayed as the green, dashed line in the three graphs (a-c). The red, solid lines show the AUC’s for the models after addition of MRI reading.
The model for routine reading has an AUC of 0.81 (a), both models with expert MRI reading have an AUC of 0.87 (b-c).
doi:10.1371/journal.pone.0094233.g003
3T Breast MRI for Diagnosis of Nonpalpable Lesions
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and conventional imaging in the evaluation of index lesions in the
breast. This effect might even be underestimated, because in the
current study, only clinically occult (nonpalpable) lesions were
included.
We observed a difference in the diagnostic performance
between routine reading during the initial study and expert
reading afterwards. This difference can be explained by several
reasons. First, the MONET study was performed shortly after the
introduction of breast MRI in clinical practice. Through the years,
more knowledge about MRI reading was acquired, especially in
the assessment and evaluation of lesions showing non-mass-like-
enhancement. A large percentage of malignancies in this study
consisted of pure DCIS (42.3%). Rosen et al. report that pure
DCIS in 59.4% of the cases is visualized as non-mass-like-
enhancement on breast MRI [23]. Differentiation between benign
and malignant is challenging in these lesions, because of the
absence of the typical malignant wash-out pattern and poorly
defined boundaries in non-mass-like lesions [24–26]. Second,
during expert reading, all breast MRI examinations were analyzed
using computer aided diagnosis (CAD) software (CADstream,
Confirma, Chicago, Illinois), a dedicated software tool for the
automatic analysis of breast lesions. The diagnostic performance
has been shown to improve when readers use a dedicated CAD
system for dynamic breast MRI analysis [27,28]. Third, the expert
readers were allowed to exclude MRI examinations if, to their
opinion, the quality of the exam was not sufficient to read. Also
this can partly explain the difference between routine and expert
reading. We observed fair to moderate interobserver agreement
between the three MRI readings. Previous studies have shown the
presence of significant interobserver variation and a considerable
learning curve in the interpretation of breast MRI [29].
This study has a some limitations. Sensitivity and specificity for
mammography and ultrasound were not described, because the
study population consisted of patients with BI-RADS 3-5 lesions
on mammography or ultrasound only. To assure that histopath-
ological confirmation was available for all lesions, we only assessed
the index lesions of which LCNB was performed. Any potential
multifocal, multicentric or contralateral lesions were not included
in the analyses, while breast MRI is currently often used to detect
multifocal or multicentric disease [5]. In this study, the BI-RADS
MRI cut-off value for malignancy was set at BI-RADS 3, because
in our hospital, many BI-RADS 3 patients are referred for biopsy.
This, however, resulted in a lower specificity. Another shortcom-
ing of our study was the fact that MR readings (both routine and
expert reading) were performed by different radiologists than
reading of conventional imaging. Furthermore, MRI reading in a
review setting can induce bias by over reading, which may have
resulted in the lower specificity we found during expert reading.
Finally, we cannot draw any conclusions from a therapeutic
perspective. This study exclusively reports on the diagnostic
performance of 3.0 Tesla breast MRI. However, our results
indicate that the evaluation and handling of information on breast
MRI in clinical practice may not be optimal.
In conclusion, this study indicates that 3.0 T breast MRI of
nonpalpable breast lesions is of added diagnostic value in the
diagnosis of in situ and invasive breast cancer. More evidence,
however, is needed to support this conclusion.
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